Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial

BACKGROUND: Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular death and risk factors, aside from lowering plasma glucose levels. With this stu...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovasc Diabetol
Main Authors: Natali, Andrea, Nesti, Lorenzo, Fabiani, Iacopo, Calogero, Enrico, Di Bello, Vitantonio
Format: Artigo
Language:Inglês
Published: BioMed Central 2017
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5639750/
https://ncbi.nlm.nih.gov/pubmed/29025406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0615-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items